Extended Data Table 3 Characteristics of studied participants and traits in the UK Biobank exome cohort
From: Exploring the complex spectrum of dominance and recessiveness in genetic cardiomyopathies
Participants, n | 454162 | Â | Â |
Female, n (%) | 246303 (54.23) | Â | Â |
European ancestry, n (%) | 428872 (94.4) | Â | Â |
Age at enrolment, mean (SD) | 57.04 (8.09) | Â | Â |
Age at last follow-up, mean (SD) | 68.00 (8.06) | Â | Â |
Disease endpoint | Cases, n (%) | Controls, n (%) | Â |
Dilated cardiomyopathy (DCM) | 924 (0.21) | 438722 (99.79) | Â |
Hypertrophic cardiomyopathy (HCM) | 538 (0.12) | 453624 (99.88) | Â |
Atrial fibrillation or flutter (AF) | 29149 (6.42) | 425013 (93.58) | Â |
Supraventricular tachycardia (SVT) | 4836 (1.06) | 449326 (98.94) | Â |
Ventricular tachycardia (VT) | 2297 (0.51) | 451865 (99.49) | Â |
Heart failure (HF) | 13791 (3.04) | 440268 (96.96) | Â |
Quantitative MRI endophenotype | Samples with data, n (%) | Mean (SD) | Median [Q1; Q3] |
LVEF | 38066 (8.38) | 0.602 (0.061) | 0.604 [0.565; 0.642] |
LVEDV (BSA indexed) | 36818 (8.11) | 75.651 (13.487) | 74.512 [66.415; 83.632] |
LVESV (BSA indexed) | 36818 (8.11) | 30.354 (8.181) | 29.441 [24.803; 34.803] |
LVSV (BSA indexed) | 36818 (8.11) | 45.297 (8.097) | 44.869 [39.889; 50.234] |
RVEF | 36078 (7.94) | 0.594 (0.064) | 0.594 [0.553; 0.635] |
RVEDV (BSA indexed) | 34893 (7.68) | 70.08 (13.705) | 68.614 [60.409; 78.295] |
RVESV (BSA indexed) | 34893 (7.68) | 28.672 (7.954) | 27.723 [23.012; 33.445] |
RVSV (BSA indexed) | 34893 (7.68) | 41.408 (8.381) | 40.705 [35.7; 46.262] |
LVMmax (BSA indexed) | 37044 (8.16) | 54.849 (10.124) | 53.728 [47.467; 61.114] |
FWmax (BSA indexed) | 36811 (8.11) | 39.586 (7.484) | 38.808 [34.184; 44.148] |
IVSmax (BSA indexed) | 37075 (8.16) | 16.68 (3.255) | 16.318 [14.327; 18.669] |